Supriya Lifescience Q1 Review – Improving Capabilities Towards Sustainable Growth: KRChoksey


BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

KRChoksey Research Report

During Q1 FY23, Supriya Lifescience Ltd. reported revenue of Rs 1,037 million (up 31.43% YoY / down 43.98% QoQ). Such growth was mainly driven by strong sales from analgesic/anestetic segment which contributed 51% to the topline against 15% in same period last year.

On operational front Ebitda in Q1 FY23 stood at Rs 337 million but dipped on QoQ basis by 57.44%, operating profit margin improved by 1,035 basis points YoY and was largely impacted QoQ which came at 32.46% in Q1 FY23.

Increase in the cost of solvents weighed on the Ebitda margins during the quarter.

Supriya Lifescience’s net profit in Q1 FY23 stood at Rs 252 million against 77 million in Q1 FY22 and it was down by 45.45% on QoQ basis. Net profit margin came at 24.30%, up 1,454 bps YoY and down marginally by 66 bps on QoQ basis.

Click on the attachment to read the full report:


This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.


Source link

What is your reaction?

In Love
Not Sure

You may also like

Comments are closed.

More in:Business